Lemborexant

Generic Name
Lemborexant
Brand Names
Dayvigo
Drug Type
Small Molecule
Chemical Formula
C22H20F2N4O2
CAS Number
1369764-02-2
Unique Ingredient Identifier
0K5743G68X
Background

Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to "switc...

Indication

Lemborexant is indicated for the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

Associated Conditions
Insomnia
Associated Therapies
-
Clinical Trials
Related News

Lemborexant on Improving Sleep Quality Among Hospital Rotating Shift Workers

Phase 3
Recruiting
Conditions
Sleep
Interventions
Drug: Placebo
Drug: Lemborexant
First Posted Date
2024-07-11
Last Posted Date
2024-07-11
Lead Sponsor
Phramongkutklao College of Medicine and Hospital
Target Recruit Count
50
Registration Number
NCT06496282
Locations
🇹🇭

Phramongkutklao Hospital, Ratchathewi, Bangkok, Thailand

Lemborexant Treatment of Insomnia Linked to Epilepsy

Phase 3
Recruiting
Conditions
Epilepsy
Sleep
Interventions
Drug: Lemborexant
Drug: Placebo
First Posted Date
2024-02-16
Last Posted Date
2024-05-08
Lead Sponsor
University of Manitoba
Target Recruit Count
26
Registration Number
NCT06262594
Locations
🇨🇦

Health Sciences Centre, Winnipeg, Manitoba, Canada

Lemborexant vs Zopiclone vs Clonidine for Insomnia Treatment in Chronic Pain Patients

Completed
Conditions
Chronic Insomnia
Chronic Pain
First Posted Date
2022-11-16
Last Posted Date
2024-05-14
Lead Sponsor
Salem Anaesthesia Pain Clinic
Target Recruit Count
150
Registration Number
NCT05618002
Locations
🇨🇦

Salem Anaesthesia Pain Clinic, Surrey, British Columbia, Canada

A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder

First Posted Date
2022-10-26
Last Posted Date
2024-11-19
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
65
Registration Number
NCT05594589
Locations
🇰🇷

Keimyung University Dongsan Hospital, Daegu-si, Korea, Republic of

🇰🇷

Gacheon University Gil Medical Centre, Incheon, Korea, Republic of

🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

and more 6 locations

Lemborexant in Delayed Sleep Phase Syndrome

Phase 4
Recruiting
Conditions
Delayed Sleep Phase Syndrome
Interventions
Drug: Lemborexant
Drug: Placebo
First Posted Date
2022-07-19
Last Posted Date
2024-06-17
Lead Sponsor
Stanford University
Target Recruit Count
60
Registration Number
NCT05463861
Locations
🇺🇸

Stanford Univeristy, Redwood City, California, United States

Lemborexant Shift Work Treatment Study

First Posted Date
2022-04-25
Last Posted Date
2024-06-27
Lead Sponsor
University of California, San Francisco
Target Recruit Count
45
Registration Number
NCT05344443
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

A Study to Evaluate Lemborexant in Milk of Healthy Lactating Women

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Lemborexant
First Posted Date
2021-05-18
Last Posted Date
2021-09-05
Lead Sponsor
Eisai Inc.
Target Recruit Count
8
Registration Number
NCT04890561
Locations
🇺🇸

PPD Phase 1 Clinic, Las Vegas, Nevada, United States

Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder

First Posted Date
2021-03-26
Last Posted Date
2024-11-13
Lead Sponsor
Virginia Commonwealth University
Target Recruit Count
18
Registration Number
NCT04818086
Locations
🇺🇸

Virginia Commonwealth University, Richmond, Virginia, United States

A Study to Evaluate the Safety of DAYVIGO (Lemborexant) Tablets in Participants With Insomnia.

First Posted Date
2020-10-05
Last Posted Date
2022-04-05
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
550
Registration Number
NCT04573556
Locations
🇯🇵

Eisai trial site 1, Nagoya, Japan

🇯🇵

Eisai trial site 3, Tokyo, Japan

🇯🇵

Eisai trial site 2, Osaka, Japan

A Single and Multiple Dose Study of Lemborexant in Healthy Chinese Participants

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: Lemborexant
First Posted Date
2020-09-21
Last Posted Date
2021-07-19
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
26
Registration Number
NCT04555733
Locations
🇨🇳

Xuhui Central Hospital, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy